Boroden has had the "hot hand" recently, accurately predicting the market's June 24 bottom. Using a weekly chart of the S&P 500 going back to October 2011, Boroden noted that all four of the averages big declines fell into a similar pattern, both in size and duration. Applying that pattern to today's rally, Boroden had a target of 1721 and another of 1765 for the S&P.
Looking longer term, Boroden also looked at a monthly chart of the S&P 500 going back to 1996. Using the same analysis, she offered up a longer-term goal of 1823 for the index.
Cramer said he sees little standing in the way of achieving Boroden's targets, especially given how wrong the bears have been thus far.
Cramer's Favorite Banks
Lightning RoundIn the Lightning Round, Cramer was bullish on Zynga (ZNGA). Cramer was bearish on Pembina Pipeline (PBA), NQ Mobile (NQ), BHP Billiton (BHP), JC Penney (JCP) and Electronic Arts (EA).
Executive Decision: Robert GouldIn the "Executive Decision" segment, Cramer sat down with Robert Gould, CEO of Epizyme (EPZM - Get Report), a recent biotech IPO that's already roared 140% in just its first six weeks of trading. Gould explained that Epizyme's approach to cancers like leukemia and lymphoma is to use targeted therapeutics to first identify specific genetic defects in patients, then deliver drugs that target those defects. Gould traced much of his company's success back to the Human Genome Project, which mapped the entire DNA sequence. He said based on that research, Epizyme is now identifying what goes wrong in a cell's DNA to turn it into cancer. One day, Epizyme hopes to replace bone marrow transplants and other "carpet bomb"-style treatments with ones targeted specifically for each individual. The promise for this therapy is welcomed by the Food and Drug Administration, he said, which he hopes will be offering accelerated timelines for drug approvals once the platform has proven itself. Cramer said that while all of Epizyme's diagnostics and treatments are still in Phase I testing, the company holds much promise for patients and shareholders.
No Huddle OffenseIn his "No Huddle Offense" segment, Cramer opined on the surprise negative pre-announcement from UPS (UPS). Cramer said UPS clearly has a lot of headwinds to fight including a slowing global economy, consumers being less willing to pay for faster shipping and a slowing industrial economy here at home. He said all of these factors are exactly what happens when there is no lending and no small business formation as we have in today's economy. The UPS news proves investors cannot play the recovery with just any stock but must continue to do their homework. To watch replays of Cramer's video segments, visit the Mad Money page on CNBC. -- Written by Scott Rutt in Washington, D.C. To email Scott about this article, click here: Scott Rutt Follow Scott on Twitter @ScottRutt or get updates on Facebook, ScottRuttDC
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts